PRODUCT RANGE

Currently MYND BIO are in the process of finalising a manufacturing & distribution license for pharmaceutical grade MDMA. MYND BIOTECH PORTUGAL is also applying for a pharmaceutical psychotropic license to manufacture and distribute a full range of pharmaceutical & psychotropic Medicines globally.

MDMA

Psychoactive drug that acts as a stimulant and releases chemicals in your brain to give an energising effect, heighten your senses, and boost emotions like self-awareness and empathy. Experts are tapping into MDMA’s effects as part of therapy for severe post traumatic stress disorder (PTSD) along with other mental health conditions.

Experts have found that when people with PTSD are given a certain amount of MDMA in a clinical setting, it helps them open up, so they can work through traumatic events.

MDMA (which is short for methylenedioxy methamphetamine) causes the release of neurotransmitters, chemical messengers to brain cells that change brain activity. They include “feel-good” hormones like dopamine, serotonin, and norepinephrine, as well as oxytocin, prolactin, cortisol, and vasopressin.

PSILOCYBIN

Psilocybin, a classic hallucinogen, is a chemical produced by more than 100 species of mushrooms worldwide. It has high affinity for several serotonin receptors, including 5-HT1A, 5-HT2A, and 5-HT2C, located in numerous areas of the brain, including the cerebral cortex and thalamus. With legislation introduced in 1992, more work is being done to further understand the implications of psilocybin use in a number of disease states. Certain mental health disease states and symptoms have been studied, including depressed mood, anxiety disorders, obsessive-compulsive disorder, alcohol use disorder, and tobacco use disorder. There has been and continues to be in-depth reviews of the study design and results of psilocybin in each of these conditions and the clinical potential for use.

KETAMINE

Ketamine can produce feelings of unreality; visual and sensory distortions; a distorted feeling about one’s body; temporary unusual thoughts and beliefs; and a euphoria or a buzz.

The drug’s potential as a treatment for depression and antidote to suicidal thoughts has drawn researchers’ attention.

They’ve studied and administered it in controlled, clinical settings to help with treatment-resistant depression and other

doctors have developed a protocol for medically supervised use that may help people who don’t get relief from other medications.

Doctors are reaching out in a new way to patients who have not responded to other kinds of mental health treatments.

Ketamine comes in several forms. The only one that the FDA has approved as a medication for depression is a nasal spray called esketamine (Spravato). It’s for adults who either haven’t been helped by antidepressant pills, have major depressive disorder, or are suicidal. They continue on their antidepressant and receive esketamine at a doctor’s office or in a clinic, where a health care provider watches over them for 2 hours after the dose. For treatment-resistant depression, patients usually get the nasal spray twice a week for 1 to 4 weeks; then once a week for weeks 5 to 9; and then once every week or 2 after that.

Further research & development of Ketamine is occuring to better understand how this medicine can be used effectively.

NEXT GEN

The psychotropic medical industry is working on next generation medicines that improve on previously released psychotropic drugs. MYND BIOTECH works with leading industry research and development companies globally to bring these to market.

Get Started

Join us in revolutionizing mental health treatment. Whether you’re a potential partner, investor, or someone passionate about advancing mental health care, there’s a way for you to contribute. Discover how you can be part of our journey to develop and distribute next-generation psychotropic medicines.